Efficacy of Combination Chemotherapy and Ablative Radiotherapy (SBRT) as First-Line Treatment in Locally Advanced Inoperable Pancreatic Cancer

What this Trial Is About

This research aims to evaluate the effectiveness and safety of combining systemic chemotherapy with ablative stereotactic body radiotherapy (SBRT) as the first treatment approach for adults with locally advanced, inoperable pancreatic cancer. The study focuses on assessing the tumor response to SBRT following chemotherapy, as well as measuring the time until the disease progresses and monitoring treatment-related side effects. Conducted in Slovenia, this non-randomized prospective clinical trial includes patients from multiple clinical centers. Participants start with standard first-line systemic chemotherapy, such as modified FOLFIRINOX or gemcitabine plus nab-paclitaxel, given according to usual clinical practice. Those whose cancer does not progress after chemotherapy receive ablative SBRT targeting the primary pancreatic tumor. After SBRT, systemic therapy may continue based on clinical evaluation and institutional guidelines. This combination treatment strategy is being studied to understand its impact on tumor control and safety. During the study, patients undergo evaluations to measure the treatment response within 12 weeks after completing SBRT. Researchers also monitor how long it takes for the disease to progress over a period of up to 36 months. Safety and tolerability are assessed by tracking any acute or late side effects related to the treatment. Participation involves regular clinical assessments and follow-up visits to collect data on outcomes and monitor patient wellbeing throughout the study period.

Combined Chemotherapy And Ablative Radiotherapy (SBRT) As First-Line Treatment In Locally Advanced Inoperable Pancreatic Cancer (SBRT-PANC)